PCM
BVS icon

Pentwater Capital Management’s Bioventus BVS Stock Holding History

Pentwater Capital Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-33,368
Closed -$472K – 217
2021
Q3 		$472K Sell
33,368
-632
-2% -$9.72K ﹤0.01% 215
2021
Q2 		$598K Sell
34,000
-21,000
-38% -$338K ﹤0.01% 233
2021
Q1 		$840K Buy
+55,000
New +$783K 0.01% 239

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Pentwater Capital Management's BVS Position: Q4 2021 in Review

Pentwater Capital Management sold out of Bioventus (BVS) in Q4 2021, closing a stake of 33,368 shares — an estimated $472K sold.

Pentwater Capital Management first reported a position in BVS in Q1 2021 and held it in 3 quarters. The position peaked at $840K in Q1 2021. 98 funds tracked by Wall St. Rank hold BVS as of Q4 2021.

  • Pentwater Capital Management reported no remaining Bioventus position as of Q4 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 33,368 Bioventus shares in Q4 2021, an estimated $472K.
  • Pentwater Capital Management first reported a position in Bioventus in Q1 2021 and held it in 3 quarters.
  • Pentwater Capital Management's Bioventus position peaked at $840K in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Bioventus as of Q4 2021.

Based on Pentwater Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.